Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer.
OBJECTIVE
Oxaliplatin-induced chronic peripheral neurotoxicity (OXCPN) manifests as a loss of sensation and dysesthesia in the distal extremities, which may impair daily activities and increase in incidence with the amount of oxaliplatin delivered. The variation in the reported incidence and severity of OXCPN may be a consequence of differences in the baseline characteristics of patients.


METHODS
This was a prospective study (ClinicalTrials.gov, NCT00977717) in which OXCPN was recorded for all consecutive colon cancer patients treated at Samsung Medical Center (Seoul, Korea) with oxaliplatin-based combination chemotherapy. The primary endpoint was the incidence of severe OXCPN (grade 2 lasting for >7 days, or grade 3). The association of severe OXCPN and pretreatment parameters was evaluated using a multivariate regression model.


RESULTS
Between Jan 2008 and Feb 2010, 100 patients treated with adjuvant folinic acid/fluorouracil plus oxaliplatin (FOLFOX) and 266 patients treated with capecitabine plus oxaliplatin (XELOX) or FOLFOX for advanced disease were registered into our study. The median cumulative dose of oxaliplatin was 796 mg/m(2) (range, 85 to 1,583 mg/m(2)). Severe OXCPN was observed in 126 (34%) patients. Overall, 43 patients discontinued chemotherapy due to toxicity: 23 without severe OXCPN and 20 with severe OXCPN. In univariate analysis, severe OXCPN was frequently observed in patients with age ≥55 years (p<0.01), stage II or III (p<0.01), adjuvant setting (p=0.01), FOLFOX (p<0.01), performance status of 0 (p=0.02), and those with no prior chemotherapy (p<0.01). In a multivariate regression model, the number of chemotherapy cycles and the cumulative oxaliplatin dose were not associated with the development of severe OXCPN.


CONCLUSIONS
We failed to find a significant association between patient characteristics at baseline and the development of severe OXCPN after oxaliplatin-based combination chemotherapy. Pharmacogenomic profiling using genome-wide association study in these patients is underway.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kyung Kee
KK
Baek
Jeeyun
J
Lee
Se Hoon
SH
Park
Joon Oh
JO
Park
Young Suk
YS
Park
Ho Yeong
HY
Lim
Won Ki
WK
Kang
Yong Beom
YB
Cho
Seong Hyeon
SH
Yun
Hee Cheol
HC
Kim
Woo Yong
WY
Lee
Ho-Kyung
HK
Chun
Clin Cancer Res. 2006 May 15;12(10):3050-6
16707601
J Clin Oncol. 2004 Jan 1;22(1):23-30
14665611
J Clin Oncol. 2007 Apr 1;25(10):1247-54
17401013
Clin Cancer Res. 2007 Nov 1;13(21):6359-68
17975148
Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46
15871765
Oncologist. 2010;15 Suppl 2:13-8
20489192
Mol Cancer Ther. 2009 Jan;8(1):10-6
19139108
Cancer Treat Rev. 2005 Apr;31(2):90-105
15847979
Neurology. 2003 Nov 11;61(9):1297-300
14610145
Mol Pharmacol. 1998 Nov;54(5):770-7
9804612
J Clin Oncol. 2005 Jul 10;23(20):4553-60
16002847
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13
14523789
Ann Oncol. 1998 Oct;9(10):1053-71
9834817
Cancer Treat Rev. 2008 Jun;34(4):368-77
18281158
N Engl J Med. 2004 Jun 3;350(23):2343-51
15175436